ERBB2 and benign prostatic hyperplasia: An IHC analysis of 53 primary PC and 9 BPH tissue samples showed that 33% of PC samples expressed HER2 without gene amplification as measured by polymerase chain reaction and 36-month patient follow-up revealed no correlation with disease progression [56].